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Mouse colonThe aim of this study was to analyze whether arginine vasopressin (AVP) may be considered a modulator of
intestinal motility. In this view, we evaluated, in vitro, the effects induced by exogenous administration of AVP
on the contractility of mouse distal colon, the subtype(s) of receptor(s) activated and the action mechanism.
Isometric recordings were performed on longitudinal and circular muscle strips of mouse distal colon. AVP
(0.001 nM–100 nM) caused concentration-dependent contractile effects only on the longitudinal muscle,
antagonized by the V1 receptor antagonist, V-1880. AVP-induced effect was not modiﬁed by tetrodotoxin,
atropine and indomethacin. Contractile response to AVP was reduced in Ca2+-free solution or in the presence
of nifedipine, and it was abolished by depletion of calcium intracellular stores after repetitive addition of carbachol
in calcium-freemediumwith addition of cyclopiazonic acid. U-73122, an inhibitor of the phospholipase C, effectively
antagonized AVP effects, whilst it was not affected by an adenylyl cyclase inhibitor. Oxytocin induced an excitatory
effect in the longitudinalmuscle of distal colon at very high concentrations, effect antagonizedbyV-1880. The results
of this study shown that AVP, via activation of V1 receptors, is able to modulate positively contractile activity of
longitudinal muscle of mouse distal colon, independently by enteric nerve activation and prostaglandin synthesis.
Contractile response is achieved by increase in cytoplasmatic Ca2+ concentration via extracellular Ca2+ inﬂux
from L-type Ca2+ channels and via Ca2+ release from intracellular stores through phospholipase C pathway.
No modulation has been observed on the contractility of the circular muscle.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Arginine-vasopressin (AVP), also known as antidiuretic hormone,
is a peptide hormone synthesized in the hypothalamus which plays a
major role in maintaining cardiovascular and body ﬂuid homeostasis.
In addition, it exerts a variety of physiological effects on various tissues
and cells, including promotion of blood coagulation, glycolysis and cell
proliferation [1,2].
The multiple actions of AVP are mediated bymembers of G-protein-
coupled receptor family divided into three subtypes: V1 receptors
(known as V1a), V2 receptors and V3 receptors (previously known as
V1b) [2,3]. V1 receptors (known as V1a) are involved in the regulation
of blood pressure [4] and are expressed in various tissues including
vascular smooth muscle cells where their activation causes vaso-
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l-bis(β-aminoethyl ether)-N,N,
tinal; U-73122, {1-[6((17β-3-
rrole-2,5-dione}; PLC, phospho-
-Tyr2,Arg8]-Vasopressin.
cnologie Biologiche, Chimiche e
ale, Università di Palermo, Viale
09; fax: +39 091 6577501.
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are involved in the regulation of the hypothalamic–pituitary–adrenal
stress axis [6,7]. V1a and V1b receptors effectively couple to Gq and
phospholipase C pathway, V2 receptors couple to Gs and adenylyl cy-
clase pathway [2].Moreover, V1 receptors via phospholipaseA2/cycloox-
ygenase pathway may induce prostaglandin E2 production in different
organs and tissues [8,9].
Although it is well known that AVP is secreted into the circulation
from the neurohypophysis in response to various factors, including
increases in plasma osmolality, emotional stress, emesis, etc., different
studies indicate the existence of peripheral site of production for this
hormone as the gut [10–13]. Moreover, most of the factors triggering
AVP release (plasma osmolality, stress, emesis etc.) have also an impact
on gastrointestinal (GI) function. AVP has been reported to regulate
electrolyte and water transport in the colon both in vivo and in vitro.
In vivo, in the rat and human colon AVP inhibits Na+ andCl− absorption
[14,15]. By the contrast, AVP, stimulates in vitro NaCl and water
absorption, as well as inhibits Cl− secretion in mouse, rat and human
colon [16–21]. Unclear and conﬂicting are the studies about a possible
effect of AVP in the control of gastrointestinal motility. Voderholzer
et al. [22] suggested that AVP at physiological level might not inﬂuence
colonic motility in rats and humans. Ward et al. [23] reported that AVP
at low concentration increased slow wave activity and phasic contrac-
tion in the muscle strips from dog colon, whilst at higher concentration
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mRNA at various levels along the GI tract has been demonstrated
in humans [6] and V1a receptors has been found on the neurons of
myenteric plexus in rat stomach, where AVP has been suggested to act
as neuromodulator of enteric cholinergic neurons inducing excitatory
effects on the contractility [24]. Recently AVP was shown to inhibit the
contractions through production of nitric oxide in strips of the circular
muscle of rat colon [25]. All together these data would suggest that
AVP may be one of the brain–gut peptides inﬂuencing gastrointestinal
functions also acting at peripheral level.
Thus, taken into account that the role of AVP in the bowel motility is
far from being clear, and that in mouse colon a recent study indicates
that another hormone, i.e. angiotensin II, involved in water control
balance [26] is able to modulate colonic contractility, the aim of this
study was to analyze pharmacologically the effects of AVP on mouse
distal colon motility, to characterize the subtype(s) of receptor(s) in-
volved and to investigate the action mechanism.
2. Materials and methods
All animal procedures were in conformity with the Italian D.L.
no. 116 of 27 January 1992 and associated guidelines in the European
Communities Council Directive of 24 November 1986 (86/609/ECC).
Adult male mice (C57BL/10SnJ; weighing 25.5 ± 0.5 g), obtained from
Charles River Laboratories (Calco — Lecco, Italy), were housed in groups
(ﬁve per cage), under controlled conditions (12/12 light/dark cycle;
ambient temperature 22 ± 1 °C; humidity 55 ± 5%) and they had free
access to tap water and standard pellet food. Experimental procedures
were approved by Ministero della Sanità (Rome, Italy).
2.1. Recording of mechanical activity
Themethod has been described previously [27,28] with somemodiﬁ-
cation. Brieﬂy,micewere euthanizedusing isoﬂurane anesthesia followed
by cervical dislocation. The abdomen was immediately opened, and the
colon was removed and placed in Krebs solution consisting of (mM):
NaCl = 119; KCl = 4.5; MgSO4 = 2.5; NaHCO3 = 25; KH2PO4 = 1.2;
CaCl2 = 2.5; and glucose = 11.1. Circular or longitudinal muscle strips
(20 mm in length) of mouse distal colon (about 5 mm proximal to the
anus) were suspended in a 10-mL organ bath with oxygenated (95% O2
and 5% CO2) Krebs solution (37 °C). The distal end of each strip was tied
to an organ holder and the proximal end was secured with a silk thread
to an isometric force transducer (FORT 25, Ugo Basile, Biological Research
Apparatus, Comerio, VA, Italy). Mechanical activity was digitized on an
A/D converter, visualized, recorded and analyzed on a personal computer
using the PowerLab/400 system (Ugo Basile, Italy). Preparations were
subjected to an initial tension of 200 mg and were allowed to equilibrate
for at least 30 min. Rhythmic spontaneous contractions of varying ampli-
tude developed in all preparations.
2.2. Experimental protocol
After the equilibration time, preparations were challenged with
0.1 μM isoproterenol or with 10 μMcarbachol (CCh) for 2 min, until sta-
ble responses were obtained. The contractile response to CCh in circular
and longitudinal muscle strips was 1.06 ± 0.18 g and 1.32 ± 0.19 g
(n = 48), respectively. The inhibitory response to isoproterenol in cir-
cular muscle strips was 0.20 ± 0.02 g (n = 48), whilst in longitudinal
strips was 0.23 ± 0.07 g (n = 48). Concentration-dependent curves
for vasopressin were constructed by non cumulative addition of the
drug before and after the different drugs. Vasopressin was applied for
approximately 3 min at 30 min intervals. Time control experiments
showed that a second curve to the agonist was reproducible. Tetro-
dotoxin (TTX) or atropine was tested against a sub-maximal dose of
AVP. To investigate the role of extracellular Ca2+ ions in the vasopressin
contractions, nifedipine, L-type voltage-dependent calcium channelblocker, or a calcium free solution were used. Calcium free solution
was made by omitting CaCl2 from the control Krebs solution with the
addition of 100 μM ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-
tetraacetic acid tetrasodium salt (EGTA). To deplete the intracellular
calcium stores tissue was incubated in Ca2+ -free solution and in the
presence of cyclopiazonic acid (CPA, 10 μM) for 15 min and subsequent
exposures to carbachol (10 μM) were repeated until carbachol had no
contractile effects [29]. Vasopressin was tested also in the presence of
U-73122, a widely used speciﬁc inhibitor of phospholipase C, indometh-
acin, a cyclooxygenase inhibitor, and in the presence of DDA, an adenylyl
cyclase inhibitor. Lastly, we tested the effects of 0.1 μM oxytocin.
All antagonists/inhibitors were left in contact to the tissue for at least
30 min adding AVP. Concentrations of the drugs used were determined
from the literature.
2.3. Solution and drugs
The following drugs were used: carbachol (CCh), cyclopiazonic acid
(CPA), 2′,3′-dideoxyadenosine (DDA), ethylene glycol-bis(β-aminoethyl
ether)-N,N,N′,N′-tetraacetic acid tetrasodium salt (EGTA), indomethacin,
isoproterenol, nifedipine, tetrodotoxin (TTX), [deamino-Pen1, O-Me-
Tyr2, Arg8]-vasopressin (V-1880) (all purchased from Sigma-Aldrich,
Inc., St. Louis, USA); arginine vasopressin (AVP) and oxytocin (Tocris
Bioscience, Bristol, UK); {1-[6((17β-3-methoxyestra-1,3,5(10)-trien-17-
yl)amino)hexyl]-1H-pyrrole-2,5-dione} (U-73122) (Calbiochem, Darm-
stadt, Germany). Indomethacin solution was prepared fresh on the day
of experiment in 2% sodium carbonate solution and the pH was adjusted
to 7.4. U-73122 and DDA were dissolved in dimethyl sulfoxide and
nifedipine was dissolved in ethanol and further diluted in Krebs. All the
other drugs were dissolved in distilled water. Control experiments using
the different solvents alone showed that none had effects on the tissue
responses that were studied. The working solutions were prepared
fresh on the day of the experiment by diluting the stock solutions in
Krebs.
2.4. Statistical analysis
All data are presented as means ± SEM: ‘n’ indicates the number
of animal preparations. Contractile responses induced by AVP were
reported as a percentage of the effect induced by 10 μM CCh. AVP
responses were ﬁtted to sigmoid curves (Prism 4.0, Graph-PAD,
San Diego, CA, USA) and EC50 values with 95% conﬁdence limits
(CLs) were determined. Statistically signiﬁcant differences were calcu-
lated by Student's t-test. P b 0.05was considered statistically signiﬁcant.
3. Results
Circular and longitudinal muscle strips of mouse distal colon
displayed spontaneous activity consisting of phasic contractions with
amplitude of 238.8 ± 0.5 mg and 244.2 ± 0.8 mg (n = 20), a fre-
quency of 4.2 ± 1.5 c.p.m. and 5.2 ± 1.5 c.p.m (n = 20), respectively.
AVP (0.001 nM–100 nM) was without any effects on the circular
muscle, whilst it caused concentration-dependent contractile ef-
fects on the longitudinal muscle (EC50 = 0.05 nM; 95% CL 0.03–
0.1 nM, n = 10) (Figs. 1, 2). These effects lasted throughout the
drug application time. The maximal response was observed at the
dose of 100 nM consisting in an absolute increase in muscular
tone of 580 ± 7.6 mg (n = 10). We never observed an inhibitory
effect in response to AVP, even at higher concentrations. The possi-
ble involvement of V1 receptor subtype in the response to AVP was
tested using, a potent V1 receptor antagonist, V-1880. V-1880 (30 nM),
which per se did not modify spontaneous activity (the amplitude
and frequency of the spontaneous contraction was 249.1 ± 0.9 mg
and 5.0 ± 1.2 c.p.m. in the presence of V-1880, n = 10), shifted to
the right the concentration–response curve to AVP (EC50 = 0.9 nM;
95% CL 0.6–1 nM, n = 10) (Fig. 2).
Fig. 1. AVP induced a contractile response only in the longitudinal muscle of mouse distal
colon. Original recordings showing the effects evoked by AVP in circular and longitudinal
of mouse distal colon.
Fig. 3.AVP contractile responses are independent by enteric nerve activation andprostaglan-
din synthesis. Histogram showing the effects of AVP (10 nM) in the absence or in the
presence of TTX (1 μM), Na+ voltage-gated neural channel blocker, atropine (1 μM), musca-
rinic receptor antagonist, or indomethacin (10 μM), cyclooxygenase inhibitor, in the longitu-
dinal muscle of mouse distal colon. Data are means ± SEM (n = 5 each) and are expressed
as percentage of themaximal effect induced by 10 μMCCh. The graphed value for the control
bar is the mean of the control data obtained before each treatment.
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voltage-gated neural channel blocker, TTX (1 μM), or atropine (1 μM),
a muscarinic receptor blocker, or indomethacin (10 μM), a cyclooxy-
genase inhibitor (Fig. 3). None of these agents had any effect on the
spontaneous mechanical activity. The amplitude and frequency of
the spontaneous contraction was: 209.1 ± 1.2 mg and 4.8 ± 1.4 c.p.m.
in the presence of TTX (n = 5); 191.3 ± 2.2 mg and 5.3 ± 0.9 c.p.m.
in the presence of atropine (n = 5); or 234.8 ± 0.9 mg and
5.2 ± 1.3 c.p.m. in the presence of indomethacin (n = 5).
In Ca2+-free solution or in the presence of a L-type calcium channel
blocker, nifedipine (10 nM), the contractile response to the submaximal
dose of AVP (10 nM) was reduced to about 30% of the control (Fig. 4).
The amplitude and frequency of the spontaneous contraction was
81.1 ± 0.9 mg and 1.2 ± 0.6 c.p.m. in Ca2+-free solution (n = 5);
83.2 ± 0.7 mg and 1.6 ± 0.7 c.p.m. in the presence of nifedipine
(n = 5). Contractile response to AVP was, also, tested after depletionFig. 2.AVP induced a contractile response in the longitudinalmuscle ofmouse distal colon via ac
by AVP in the longitudinal of mouse distal colon. B) Concentration–response curves to AVP befo
distal colon. Data are means ± SEM (n = 10) and are expressed as percentage of the maximaof calcium intracellular stores. Depletion of calcium intracellular
stores was induced by repetitive challenges with carbachol (10 μM),
cholinergic agonist, which mobilized calcium from intracellular stores,
in calcium-free medium and in the presence of CPA (10 μM), to block
reuptake of Ca2+ by sarcoplasmic reticulum-speciﬁc Ca2+-ATPase.
AVP was tested once CCh had no effect on the colonic muscle. Intivation of V1 receptors. A)Original recordings showing thedose-dependent effects evoked
re and after V-1880 (30 nM), V1 receptor antagonist, in the longitudinal muscle of mouse
l effect induced by 10 μM CCh. *P b 0.05 versus control.
Fig. 4. AVP contractile responses require Ca2+ inﬂux from L-type channel. Histogram
showing the effects of AVP (10 nM) in longitudinalmuscle ofmouse distal colon in control
condition, in Ca2+-free solution or in the presence of nifedipine (10 nM), L-type calcium
channel blocker, in the longitudinal muscle of mouse distal colon. Data are means ± SEM
(n = 5 each) and are expressed as percentage of the maximal effect induced by
10 μM CCh. The graphed value for the control bar is themean of the control data obtained
before each treatment. *P b 0.05when compared to the respective own control condition.
Fig. 6. Phospholipase C is activated by V1 receptors. Histogram showing the effects of AVP
(10 nM), in the absence or in the presence of U-73122 (50 μM), an inhibitor of the
phospholipase C, or DDA (10 μM), an adenylyl cyclase inhibitor, in the longitudinalmuscle
ofmouse distal colon. Data aremeans ± SEM(n = 5each) and are expressed as percentage
of the maximal effect induced by 10 μM CCh. The graphed value for the control bar
is the mean of the control data obtained before each treatment. *P b 0.05 when compared
to the respective own control condition.
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indicatingmobilization of calcium from intracellular stores after activa-
tion of V1 receptors (Fig. 5).
Since intracellular Ca2+ release from the sarcoplasmic reticulum
is accomplished in the gastrointestinal muscle by activation of intra-
cellular signaling transduction, the excitatory effect induced of submax-
imal dose of AVP was tested in the presence of U-73122, an inhibitor
of the PLC, and in the presence of DDA, an adenylyl cyclase inhibitor.
U-73122 (50 μM) antagonized the response by 70%, whilst, as expected,
DDA (10 μM) was without any effect (Fig. 6).
Lastly, we tested the effects of oxytocin, which differs from AVP by
only two amino acids, since it is reported tomodulate intestinalmotility
in rats [24]. In our preparation, oxytocin induced an excitatory effect in
the longitudinal muscle of distal colon only at very high concentrations,
from 0.1 μM. However, this effect was antagonized by V-1880 (30 nM),
indicating an aspeciﬁc binding of oxytocin to V1 receptors (data not
shown).Fig. 5. AVP contractile responses require calcium release from intracellular stores. Original tracin
muscle of mouse distal colon before and after depletion of intracellular Ca2+ stores achieved by
(10 μM). Note that in this condition, the contractile response to AVP was abolished.4. Discussion
The results of this study show that AVP, via activation of V1
receptors, is able tomodulate positively the contractile activity of longi-
tudinal muscle of mouse distal colon, independently by enteric nerve
activation and prostaglandin synthesis. Contractile response is achieved
by increase in cytoplasmatic Ca2+ concentration via extracellular Ca2+
inﬂux from L-type Ca2+ channels and via Ca2+ release from intracellular
stores through PLC pathway. No modulation has been observed on the
contractility of the circular muscle.
The role of AVP in the regulation of free water reabsorption, body
ﬂuid osmolality, blood volume, blood pressure, cell contraction, cell
proliferation, and adrenocorticotropin secretion, is well known, but dif-
ferent experimental evidences suggest an involvement of this hormone
also in the control of GI functions [30]. In humans, intravenous adminis-
tration of AVP, used in the treatment of upper GI hemorrhages, causes
abdominal cramps and a strong urge to defecate, likely by stimulating
colonic motility [31]. Either central or peripheral site of action have
been reported [32].gs showing the effects of AVP (10 nM) on spontaneousmechanical activity of longitudinal
repetitive addition of carbachol (10 μM) in Ca2+-free solution and in the presence of CPA
33M. Mastropaolo et al. / Regulatory Peptides 187 (2013) 29–34Indeed AVP can be produced locally in cells of human and rat gastro-
intestinal system [33] and AVP receptors are reported to be expressed
throughout gastrointestinal tract [6,24]. However, there are contra-
dictory reports of the effects of vasopressin being different the
responses in the various parts of the GI tract and among species. In
our experiments, AVP induces a concentration-dependent contractile
response on the longitudinal muscle of mouse distal colon by activation
of speciﬁc V1 receptors, as shown by the sensitivity of the response to
the selective V1 receptor antagonist V-1880. Actually, local V1 receptors
mediating either AVP excitatory or inhibitory effects have been reported
in other animal preparations [23–25].
In our preparations, we never observed inhibitory effects of AVP
even at the higher concentrations, although tissues were able to relax
in response of isoproterenol. Intriguingly, AVP responses can be selec-
tively seen only in longitudinal muscle strips, being AVP ineffective, at
our concentration range, on the circular muscle. It has been reported
that in mouse gastrointestinal muscle there is a different sensitivity of
the two muscular layers to pharmacological drugs, being the longitudi-
nal muscle layer more responsive to excitatory agents than the circular
muscle layer [34]. However, we cannot exclude that AVP may induce
both inhibitory and excitatory effects on the circular muscle which
will counterbalance each other. In any case, the excitatory effects in-
duced on the longitudinal muscle may contribute to determine the
overall muscular tone instead of propulsive motor activity. Tonic activity
would allow homogenizing of the luminal contents and increasing both
the pressure and the area of their contact with the mucosal surface,
facilitating water and salt absorption.
Moreover, the contractile effects induced by AVPwere insensitive to
drugs blocking neural conduction and cholinergic neurotransmission,
indicating a recruitment of post-junctional V1 receptors. This conclu-
sion is in agreement to results obtained in dog proximal colon [23],
but it is in contrast with other studies in monkey and rats [24,25,31],
which suggest neural mechanisms underlying AVP effects, strength-
ened species differences in the response to AVP.
Further, our study demonstrated that contractile effects of AVP
are dependent upon increase in intracellular Ca2+ concentration
due to Ca2+ inﬂux from extracellular space via L-type Ca2+ chan-
nels nifedipine-sensitive and Ca2+ release from internal stores.
Moreover, we showed that contractile responses to AVP were re-
duced in the presence of the PLC inhibitor, U-73122, indicating
that, also in our preparation, V1 receptors are coupled to the Gq pro-
tein/PLCβ pathway leading to the increase in intracellular calcium
concentration by release from intracellular stores. In addition, AVP,
via activation of V1 receptors/phospholipase A2/cyclooxygenase,
has been shown to stimulate prostaglandin E2 production human ﬁbro-
blasts [9]. However, in our preparation, prostaglandin synthesis seems
not to be involved in the excitatory effects to AVP due to the insensitivity
of the contractile response to indomethacin. As expected, AVP responses
were resistant to adenylyl cyclase inhibitor and this observation may
allow us also to exclude an involvement of V2 receptors, generally linked
to adenylyl cyclase activation and increase of intracellular cAMP.
Physiological plasma levels of AVP in rat and in mouse were
comparable to those in human, being in the order of 10−11 M
[35,36]. In our experiments, AVP at such concentrations marginally
inﬂuences colonic motility, as reported in rat colon [37], contribut-
ing to the maintenance of muscular tone. This effect will be ampliﬁed
when higher plasma concentrations of AVP will be reached, as after
water deprivation [35] at the early stage of septic shock [38–40] in
various chronic inﬂammatory states [41,42], and during the treatment
of critical illness [43,44].
In addition, expression of AVP-like immunoreactivity was found
in the GI wall, increasing in oral to aboral direction [12,13,23,31,45],
suggesting a possible local source of AVP that increasing AVP level
over the circulating concentration may be one of the factors regulating
colonic motility. Therefore, as suggested for angiotensin II [26], the
modulation of the colonic contractility and the consequent impact onmotility pattern can be one of the mechanisms by which AVP would
control body ﬂuid and electrolyte homeostasis.
Lastly, AVP differs from oxytocin by only two amino acids. Oxytocin
has been reported to induce in rats excitatory effects on the gastric
motility [24], but not on the colonic motility [46]. In our experiments,
we could see an excitatory effect to oxytocin only at very high concen-
tration (over 0.1 μM). This effect was antagonized in presence of the
V1 receptors antagonist, V-1880, suggesting that, at such high concen-
trations, oxytocin interacts aspeciﬁcally with V1 receptors. Thus, simi-
larly from what has been reported in rat colon [46], in mouse colon
oxytocin seems not to play a role in the modulation of contractility.
In conclusion, in this studywe reported that AVP can inducemuscular
contraction in longitudinal distal mouse by activation of V1 excitatory
receptors located at the post-junctional level. V1 receptors determine
increase in cytoplasmatic Ca2+ concentration via extracellular Ca2+ in-
ﬂux from L-type Ca2+ channels and via Ca2+release from intracellular
stores through PLC pathway. Overall our results underlie the possibility
that AVP is able tomodulate intestinal motility also acting at peripheral
level, although its physiological signiﬁcance remains to be elucidated.
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